Literature DB >> 10803796

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia.

R A Hauser1, J Friedlander, T A Zesiewicz, C H Adler, L C Seeberger, C F O'Brien, E S Molho, S A Factor.   

Abstract

In clinical trials for patients with Parkinson's disease (PD) with motor fluctuations, efficacy is generally ascribed to an intervention if motor function is significantly improved or if "off" time is significantly reduced. However, we have argued that patients might not be improved if off time is reduced only to the extent that unwanted dyskinesia is increased. Therefore, a home diary should include an assessment of dyskinesia to provide an accurate reflection of clinical status over a period of time. We undertook two studies to develop a home diary to assess functional status in patients with PD with motor fluctuations and dyskinesia. In both studies, patients concurrently completed a test and a reference diary. In Study I, we evaluated the impact of different severities of dyskinesia on patient-defined functional status. There were 1,149 evaluable half-hour time periods from 24 patients; 94.3% of off time was considered "bad" time and 90.2% of "on" time without dyskinesia, 72.6% of on time with mild dyskinesia, 43.0% of on time with moderate dyskinesia, and 15.2% of on time with severe dyskinesia was considered "good" time. In Study II, we evaluated a new home diary designed to separate dyskinesia that had a negative impact on patient-defined functional status from dyskinesia that did not. There were 816 evaluable time periods from 17 patients; 84.9% of off time and 89.9% of on time with troublesome dyskinesia was considered bad time while 85.5% of on time without dyskinesia and 93.8% of on time with nontroublesome dyskinesia was considered good time. With this diary (Diary II), the effect of an intervention can be expressed as the change in off time and the change in on time with troublesome dyskinesia (bad time). The sum can be used as an outcome variable and compared to baseline or across groups. In evaluating the efficacy of an intervention, assessment of change in off time and change in on time with troublesome dyskinesia provides a more accurate reflection of clinical response than change in off time alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803796     DOI: 10.1097/00002826-200003000-00003

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  83 in total

1.  DBS candidates that fall short on a levodopa challenge test: alternative and important indications.

Authors:  Takashi Morishita; Maryam Rahman; Kelly D Foote; Kyle M Fargen; Charles E Jacobson; Hubert H Fernandez; Ramon L Rodriguez; Irene A Malaty; Dawn Bowers; Christopher J Hass; Yoichi Katayama; Takamitsu Yamamoto; Michael S Okun
Journal:  Neurologist       Date:  2011-09       Impact factor: 1.398

2.  Development of digital biomarkers for resting tremor and bradykinesia using a wrist-worn wearable device.

Authors:  Nikhil Mahadevan; Charmaine Demanuele; Hao Zhang; Dmitri Volfson; Bryan Ho; Michael Kelley Erb; Shyamal Patel
Journal:  NPJ Digit Med       Date:  2020-01-15

3.  mHealth and wearable technology should replace motor diaries to track motor fluctuations in Parkinson's disease.

Authors:  M Kelley Erb; Daniel R Karlin; Bryan K Ho; Kevin C Thomas; Federico Parisi; Gloria P Vergara-Diaz; Jean-Francois Daneault; Paul W Wacnik; Hao Zhang; Tairmae Kangarloo; Charmaine Demanuele; Chris R Brooks; Craig N Detheridge; Nina Shaafi Kabiri; Jaspreet S Bhangu; Paolo Bonato
Journal:  NPJ Digit Med       Date:  2020-01-17

4.  Speech-based characterization of dopamine replacement therapy in people with Parkinson's disease.

Authors:  R Norel; C Agurto; S Heisig; J J Rice; H Zhang; R Ostrand; P W Wacnik; B K Ho; V L Ramos; G A Cecchi
Journal:  NPJ Parkinsons Dis       Date:  2020-06-12

5.  Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease.

Authors:  David Charles; Peter E Konrad; Joseph S Neimat; Anna L Molinari; Michael G Tramontana; Stuart G Finder; Chandler E Gill; Mark J Bliton; Chris Kao; Fenna T Phibbs; Peter Hedera; Ronald M Salomon; Kevin R Cannard; Lily Wang; Yanna Song; Thomas L Davis
Journal:  Parkinsonism Relat Disord       Date:  2014-03-28       Impact factor: 4.891

6.  Objective measurement of dyskinesia in Parkinson's disease using a force plate.

Authors:  Kathryn A Chung; Brenna M Lobb; John G Nutt; James McNames; Fay Horak
Journal:  Mov Disord       Date:  2010-04-15       Impact factor: 10.338

7.  Passive Monitoring at Home: A Pilot Study in Parkinson Disease.

Authors:  Zachary Kabelac; Christopher G Tarolli; Christopher Snyder; Blake Feldman; Alistair Glidden; Chen-Yu Hsu; Rumen Hristov; E Ray Dorsey; Dina Katabi
Journal:  Digit Biomark       Date:  2019-04-30

Review 8.  Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease.

Authors:  Christiana Ossig; Angelo Antonini; Carsten Buhmann; Joseph Classen; Ilona Csoti; Björn Falkenburger; Michael Schwarz; Jürgen Winkler; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2015-08-08       Impact factor: 3.575

9.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Authors:  C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini
Journal:  Lancet Neurol       Date:  2013-12-20       Impact factor: 44.182

10.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

Authors:  Hubert H Fernandez; Arvydas Vanagunas; Per Odin; Alberto J Espay; Robert A Hauser; David G Standaert; Krai Chatamra; Janet Benesh; Yili Pritchett; Steven L Hass; Robert A Lenz
Journal:  Parkinsonism Relat Disord       Date:  2013-01-01       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.